Immune checkpoint inhibitor (ICI)-induced myocarditis is a serious cardiac immune-related adverse event that can arise during immunotherapy. Prompt recognition and a structured management approach are essential in this setting.
Acute myocarditis occurring in a patient receiving immune checkpoint inhibitor therapy — a potentially life-threatening complication requiring urgent assessment and intervention.
Management involves addressing the underlying immunotherapy exposure combined with corticosteroid therapy, with the specific regimen varying according to disease severity. The complete protocol specifies the full sequence, criteria, and escalation pathway.
Full dosing guidance and severity-stratified decision criteria are available in the structured protocol below.
DOI: 10.1093/eurheartj/ehaf192